Efficacy of the polo-like kinase inhibitor rigosertib, alone or in combination with Abelson tyrosine kinase inhibitors, against break point cluster region-c-Abelson-positive leukemia cells.
about
Identification of Bisindolylmaleimide IX as a potential agent to treat drug-resistant BCR-ABL positive leukemia.FOXM1 Transcription Factor: A New Component of Chronic Myeloid Leukemia Stem Cell Proliferation Advantage.Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies.Therapeutic targeting of Aurora A kinase in Philadelphia chromosome-positive ABL tyrosine kinase inhibitor-resistant cells
P2860
Efficacy of the polo-like kinase inhibitor rigosertib, alone or in combination with Abelson tyrosine kinase inhibitors, against break point cluster region-c-Abelson-positive leukemia cells.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Efficacy of the polo-like kina ...... elson-positive leukemia cells.
@ast
Efficacy of the polo-like kina ...... elson-positive leukemia cells.
@en
type
label
Efficacy of the polo-like kina ...... elson-positive leukemia cells.
@ast
Efficacy of the polo-like kina ...... elson-positive leukemia cells.
@en
prefLabel
Efficacy of the polo-like kina ...... elson-positive leukemia cells.
@ast
Efficacy of the polo-like kina ...... elson-positive leukemia cells.
@en
P2093
P2860
P356
P1433
P1476
Efficacy of the polo-like kina ...... elson-positive leukemia cells.
@en
P2093
Juri Sakuta
Seiichi Okabe
Tetsuzo Tauchi
Yuko Tanaka
P2860
P304
20231-20240
P356
10.18632/ONCOTARGET.4047
P407
P577
2015-05-08T00:00:00Z